---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-032048"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2021-12-20T23:59:59+00:00"
generated_at: "2026-06-27T23:51:21.148409+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds

## Summary
- IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.
- Gross proceeds $21M; underwriters have 45-day option for up to 630K additional shares.
- Net proceeds to fund IMX-110 Phase 2a trial in soft tissue sarcoma and combination trial.
- Also fund IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease).
- Filed amended charter and bylaws in connection with IPO closing.

## SEC filing metadata
- accession: 0001493152-21-032048
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2021-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/0001493152-21-032048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-032048
- JSON: https://secwatch.observer/filing/0001493152-21-032048.json
- Plain text: https://secwatch.observer/filing/0001493152-21-032048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.